Eloralintide (LY3841136): Eli Lilly's Amylin Agonist — Scientific Guide
Eloralintide (LY3841136) is an amylin analog from Eli Lilly, administered as a once-weekly injection in the trials. Phase 2: 20% weight loss at 48 weeks. Phase 3 ENLIGHTEN is ongoing, combining EloraTZP with tirzepatide, and comparing it to cagrilintide and retatrutide.
